Anti-GD2 Chimeric Antigen Receptor
Showing 1 - 25 of >10,000
Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)
Completed
- Sarcoma
- +3 more
- Anti-GD2-CAR engineered T cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)
Recruiting
- Neuroblastoma
- +5 more
- GD2-CART01
-
Roma, ItalyOspedale Pediatrico Bambino Gesù
Mar 9, 2022
Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor Trial (GD2-CART01 (iC9-GD2-CAR T-cells))
Not yet recruiting
- Brain Tumor, Pediatric
- +6 more
- GD2-CART01 (iC9-GD2-CAR T-cells)
- (no location specified)
Mar 18, 2022
Relapsed or Refractory Neuroblastoma Trial in London (other, drug, genetic)
Completed
- Relapsed or Refractory Neuroblastoma
- Leukapheresis
- +3 more
-
London, United KingdomUniversity College London Institute of Child Health & Great Ormo
Jul 23, 2021
Neuroblastoma, Effects of Immunotherapy Trial in Guangzhou (Anti-GD2 CART)
Suspended
- Neuroblastoma
- Effects of Immunotherapy
- Anti-GD2 CART
-
Guangzhou, Guangdong, ChinaZhujiang Hospital of Southern Medical University
Aug 2, 2021
Neuroblastoma Trial (GD2 CAR T cells)
Not yet recruiting
- Neuroblastoma
- GD2 CAR T cells
- (no location specified)
Aug 5, 2023
Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Neuroblastoma
- GINAKIT Cells
- +2 more
-
Houston, TexasTexas Children's Hospital
Jan 18, 2023
Neuroblastoma Trial in Houston (iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan)
Active, not recruiting
- Neuroblastoma
- iC9-GD2 T Cells - frozen
- +5 more
-
Houston, Texas
- +1 more
Jan 4, 2023
Osteosarcoma, Neuroblastoma Trial in Houston (genetic, biological, drug)
Active, not recruiting
- Osteosarcoma
- Neuroblastoma
- GD2 T cells
- +3 more
-
Houston, Texas
- +1 more
Apr 16, 2021
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T Infusion)
Not yet recruiting
- Lung Cancer
- +2 more
- iC9.GD2.CAR.IL-15 T Infusion
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Nov 16, 2022
Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)
Recruiting
- Neuroblastoma
- Osteosarcoma
- iC9.GD2.CAR.IL-15 T-cells
- +2 more
-
Atlanta, Georgia
- +1 more
Jan 4, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,
Recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Manufactured Anti-BCMA CAR-T cells
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)
Not yet recruiting
- Diffuse Midline Glioma, H3 K27M-Mutant
- GD2 CAR T cells
- (no location specified)
Sep 15, 2022
Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)
Not yet recruiting
- Follicular Lymphoma
- Axicabtagene Ciloleucel
- +5 more
- (no location specified)
Sep 21, 2023
Advanced Sarcoma Trial (NKG2D-CAR memory T cell)
Not yet recruiting
- Advanced Sarcoma
- NKG2D-CAR memory T cell
- (no location specified)
Oct 17, 2023
Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)
Recruiting
- Acute Myeloid Leukemia
- Anti-CLL1 CART cells
-
Kunming, Yunnan, ChinaNo.212 Daguan Road, Xishan District
Nov 23, 2022
Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))
Recruiting
- Systemic Lupus Erythematosus (SLE)
- anti-CD19 CAR NK cells (KN5501)
-
Shanghai, ChinaChanghai Hospital
Aug 25, 2023
Solid Tumor Trial (HER2-E-CART cells)
Not yet recruiting
- Solid Tumor
- HER2-E-CART cells
- (no location specified)
Feb 16, 2023
Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)
Not yet recruiting
- Neuroendocrine Tumor (NET)
- Colorectal Cancer (CRC)
- CHM-2101 CAR-T cells
- (no location specified)
Sep 20, 2023
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed
Recruiting
- Relapsed Non Hodgkin Lymphoma
- +2 more
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
-
Calgary, Alberta, Canada
- +5 more
Jul 18, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- Autologous humanized anti-CD22 chimeric antigen receptor T cells
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)
Recruiting
- B-Cell Lymphoma
- +4 more
- 19(T2)28z1xx TRAC T cell
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023